Cancer stem-like cells: The dark knights of clinical hematology and oncology

Journal of B.U.ON.

Volumn 19, Issue 2, 2014, Pages 328-335

  Frinc, Ioana ^a,b   Muresan, Mihai Stefan ^b,c   Zaharie, Florin ^b,d   Petrov, Ljubomir ^a,b   Irimie, Alexandra ^a,b   Berce, Cristian ^b   Berindan Neagoe, Ioana ^b   Tomuleasa, Ciprian ^a,b  

^a Ion Chiricuta Comprehensive Cancer Center   (Romania)

^b IULIU HATIEGANU UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

^c Clinical Institute of Urology   (Romania)

^d Hepatology Octavian Fodor   (Romania)

Author keywords

Cancer stem cells; Clinical hematology; Clinical oncology

Indexed keywords

CANCER MORTALITY; CANCER STEM CELL; HEMATOLOGY; HISTOLOGY; HUMAN; METASTASIS; MOLECULAR BIOLOGY; MOLECULARLY TARGETED THERAPY; MORBIDITY; ONCOLOGY; PATHOLOGY; PHYSIOLOGY; REVIEW; STEM CELL NICHE;

HEMATOLOGY; HUMANS; MEDICAL ONCOLOGY; NEOPLASM METASTASIS; NEOPLASMS; NEOPLASTIC STEM CELLS; STEM CELL NICHE;

EID: 84904155077     PISSN: 11070625     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (52)

1. Müller A, Homey B, Soto H et al. Involvement of chemokine receptors in breast cancer metastasis. Nature 2001;410:50-56. (Pubitemid 32225831)
2. Liota L. An attractive force in metastasis. Nature 2001;410:24-25.
3. Chiang AC, Massagué J. Molecular basis of metastasis. N Engl J Med 2008;359:2814-2823.
4. Barbieri F, Bajetto A, Porcile C et al. CXC receptor and chemokine expression in human meningioma: SDF1/CXCR4 signaling activates ERK1/2 and stimulates meningioma cell pro- liferation. Ann N Y Acad Sci 2006;1090:332-343. (Pubitemid 47092139)
5. Tang CH, Tan TW, Fu WM, Yang RS. Involvement of matrix metalloproteinase-9 in stromal cell-derived factor-1/CXCR4 pathway of lung cancer metastasis. Carcinogenesis 2008;29:35-43. (Pubitemid 351201739)
6. Zagzag D, Krishnamachary B, Yee H et al. Stromal cell derived factor la and CXCR4 expression in hemangioblastoma and clear cell-renal cell carcinoma: von Hippel-Lindau loss of function induces expression of a ligand and its receptor. Cancer Res 2005;65:6178-6188. (Pubitemid 40994403)
7. Ehtesham M, Mapara KY, Stevenson VB, Thompson RC. CXCR4 mediates the proliferation of glioblastoma progenitor cells. Cancer Lett 2009;274:307-312.
8. Libura J, Drukala J, Majka T et al. CXCR4-SDF-1 signaling is active in rhabdomyosarcoma cells and regulates locomotion, chemotaxis and adhesion. Blood 2002;100:2597-2606.
9. Peled A, Hardan I, Trakhtenbrot L et al. Immature leukemic CD34+CXCR4+ cells from CML patients have lower integrin dependent migration and adhesion in response to the chemokine SDF-1. Stem Cells 2002;20:259-266. (Pubitemid 34507442)
10. Virchow R. Editorial archive für pathologische. Anat Physiol Klin Med 1855; 8:23-54.
11. Barker N, van de Wetering M, Clevers H. The intestinal stem cell. Genes Dev 2008;22:1856-1864. (Pubitemid 352008634)
12. Jones S, Chen WD, Parmigiani G et al. Comparative lesion sequencing provides insights into tumor evolution. Proc Natl Acad Sci U S A 2008;105:4283-4288. (Pubitemid 351754372)
13. Boman BM, Fields JZ, Cavanaugh KL, Guetter A, Runquist OA. How dysregulated colonic crypt dynamics cause stem cell overpopulation and initiate colon cancer. Cancer Res 2008;68:3304-3313.
14. Clevers H. At the crossroads of inflammation and cancer. Cell 2004;118:671-674. (Pubitemid 39221727)
15. Choi D, Lee HW, Hur KY et al. Cancer stem cell markers CD 133 and CD24 correlate with invasiveness and differentiation in colorectal adenocarcinoma. World J Gastroenterol 2009;15:2258-2264.
16. Mori Y, Yin J, Sato F et al. Identification of genes uniquely involved in frequent microsatellite instability colon carcinogenesis by expression profiling combined with epigenetic scanning. Cancer Res 2004;64:2434-2438. (Pubitemid 38523897)
17. Susman S, Tomuleasa C, Soritau O et al. The colorectal cancer stem-like cell hypothesis: a pathologist's point of view. J BUON 2012;17:230-236.
18. Pupa SM, Ménard S, Forti S, Tagliabue E. New insights into the role of extracellular matrix during tumor onset and progression. J Cell Physiol 2002;192:259-267. (Pubitemid 34827603)
19. Nash JF. Equilibrium Points in N-Person Games. Proc Natl Acad Sci U S A 1950;36:48-49.
20. Vincent TL, Gatenby RA. An evolutionary model for initiation, promotion, and progression in carcinogenesis. Int J Oncol 2008;32:729-737. (Pubitemid 351780583)
21. Basanta D, Simon M, Hatzikirou H, Deutsch A. Evolutionary game theory elucidates the role of glycolysis in glioma progression and invasion. Cell Prolif 2008;41:980-987.
22. Strand DW, Franco OE, Basanta D, Anderson AR, Hayward SW. Perspectives on tissue interactions in development and disease. Curr Mol Med 2010;10:95-112.
23. Tse JC, Kalluri R. Mechanisms of metastasis: epithelial-to-mesenchymal transition and contribution of tumor microenvironment. J Cell Biochem 2007;101:816-829. (Pubitemid 47040864)
24. Dalerba P, Dylla SJ, Park IK et al. Phenotypic characterization of human colorectal cancer stem cells. Proc Natl Acad Sci U S A 2007;104:10158-10163. (Pubitemid 47175279)
25. Ricci-Vitiani L, Lombardi DG, Pilozzi E et al. Identification and expansion of human colon-cancer initiating cells. Nature 2007;445:111-115. (Pubitemid 46067311)
26. Polyak K, Hahn WC. Roots and stems: stem cells in cancer. Nat Med 2006;12:296-300. (Pubitemid 43355075)
27. Ballinger AB, Anggiansah C. Colorectal cancer. BMJ 2007;335:715-718. (Pubitemid 47582982)
28. Mareel M, Leroy A. Clinical, cellular, and molecular aspects of cancer invasion. Physiol Rev 2003;83:337-376. (Pubitemid 36382891)
29. Subramaniam V, Gardner H, Jothy S. Soluble CD44 secretion contributes to the acquisition of aggressive tumor phenotype in human colon cancer cells. Exp Mol Pathol 2007;83:34134-346.
30. Murphy PM. Chemokines and the molecular basis of cancer metastasis. N Engl J Med 2001;345:833-835.
31. Duffy MJ, van Dalen A, Haglund C et al. Tumour markers in colorectal cancer: European Group on Tumour Markers (EGTM) guidelines for clinical use. Eur J Cancer 2007;43:1348-1360. (Pubitemid 46874070)
32. Ogino S, Brahmandam M, Cantor M et al. Distinct molecular features of colorectal carcinoma with signet ring cell component and colorectal carcinoma with mucinous component. Mod Pathol 2006;19:59-68. (Pubitemid 43250979)
33. Debruyne PR, Bruyneel EA, Karaguni IM et al. Bile acids stimulate invasion and haptotaxis in human colorectal cancer cells through activation of multiple oncogenic signaling pathways. Oncogene 2002;21:6740-6750. (Pubitemid 35221916)
34. Zeelenberg IS, Ruuls-Van Stalle L, Roos E. The chemokine receptor CXCR4 is required for outgrowth of colon carcinoma micrometastases. Cancer Res 2003;3:3833-3839. (Pubitemid 36793074)
35. Koshiba T, Hosotani R, Miyamoto Y et al. Expression of stromal cell-derived factor 1 and CXCR4 ligand receptor system in pancreatic cancer: a possible role for tumor progression. Clin Cancer Res 2000;6:3530-3535.
36. Taichman RS, Cooper C, Keller ET, Pienta KJ, Taichman NS, McCauley LK. Use of the stromal cell-derived factor-1/CXCR4 pathway in prostate cancer metastasis to bone. Cancer Res 2002;62:1832-1837. (Pubitemid 34408510)
37. Liang Z, Yoon Y, Votaw J, Goodman MM, Williams L, Shim H. Silencing of CXCR4 blocks breast cancer metastasis. Cancer Res 2005;65:967-971. (Pubitemid 40216458)
38. Ottaiano A, Franco R, Aiello Talamanca A et al. Over-expression of both CXC chemokine receptor 4 and vascular endothelial growth factor proteins predicts early distant relapse in stage II-III colorectal cancer patients. Clin Cancer Res 2006;12:2795-2803.
39. Kim J, Takeuchi H, Lam ST et al. Chemokine receptor CXCR4 expression in colorectal cancer patients increases the risk for recurrence and for poor survival. J Clin Oncol 2005;23:2744-2753. (Pubitemid 46179464)
40. Schimanski CC, Schwald S, Simiantonaki N et al. Effect of chemokine receptors CXCR4 and CCR7 on the metastatic behavior of human colorectal cancer. Clin Cancer Res 2005;11:1743-1750. (Pubitemid 40471835)
41. Emami KH, Nguyen C, Ma H et al. A small molecule inhibitor of beta-catenin/CREB-binding protein transciption. Proc Natl Acad Sci U S A 2004;101:12682-12687. (Pubitemid 39122083)
42. Tomuleasa C, Soritau O, Fischer-Fodor E et al. Arsenic trioxide plus cisplatin/ interferon α-2b/ doxorubicin/capecitabine in vitro combination chemotherapy for hepatocellular carcinoma. Hematol Oncol Stem Cell Ther 2011;4:60-66.
43. Jin L, Hope KJ, Zhai Q, Smadja-Joffe F, Dick JE. Targeting of CD44 eradicates human acute myeloid leukemic cells. Nat Med 2006;12:1167-1174. (Pubitemid 44527352)
44. Todaro M, Alea MP, Di Stefano AB et al. Colon cancer stem cells dictate tumor growth and resist cell death by production of interleukin-4. Stem Cell 2007;1:389-402. (Pubitemid 47506537)
45. Yu Y, Kanwar SS, Patel BB, Nautiyal J, Sarkar FH, Majumdar AP. Elimination of colon cancer stem-like cells by the combination of curcumin and FOLFOX. Transl Oncol 2009;2:321-328.
46. Abraham JM, Cheng Y, Hamilton JP et al. Generation of small 32P-labeled peptides as a potential approach to colorectal cancer therapy. PloS One 2008;3(6):e2508-e2514.
47. Koga S, Hirohata S, Kondo Y et al. A novel telomerase-specific gene therapy: gene trasnfer of caspase-8 utilizing the human telomerase catalytic subunit gene promoter. Hum Gene Ther 2000;11:1397-1406. (Pubitemid 30451020)
48. Komata T, Kanzawa T, Kondo Y, Kondo S. Telomerase as a therapeutic target for malignant gliomas. Oncogene 2002;21:656-663. (Pubitemid 34146268)
49. Galanis E, Hartmann LC, Cliby WA et al. Phase I trial of intraperitoneal administration of an oncolytic measles virus strain engineered to express carcinoembryonic antigen for recurrent ovarian cancer. Cancer Res 2010;70:875-882.
50. Msaouel P, Dispenzieri A, Galanis E. Clinical testing of engineered oncolytic measles virus strains in the treatment of cancer: an overview. Curr Opin Mol Ther 2009;11:43-53.
51. Ivy SP, Wick JY, Kaufman BM. An overview of small-molecule inhibitors of VEGFR signaling. Nat Rev Clin Oncol 2009;6:569-579.
52. Matsusue R, Kubo H, Hisamori S et al. Hepatic stellate cells promote liver metastasis of colon cancer cell by the action of SDF-1/CXCR4 axis. Ann Surg Oncol 2009;16:2645-2653.